The Estimation of Efficacy of Nonspecific Medications Against Hemorrhagic Fevers Caused by Arenaviruses
https://doi.org/10.37489/0235-2990-2023-68-7-8-70-77
Abstract
The article presents an analysis of studies assessing the effectiveness of new nonspecific medications against hemorrhagic fevers caused by arenaviruses. The possible targets for nonspecific medications, classes of researched antiviral preparations, methods of preclinical investigation of antiviral preparations in vitro and on laboratory animals, as well as prospects for their use in healthcare at present are considered. It has been shown that the level of development of nonspecific medications against hemorrhagic fevers caused by arenaviruses is significantly inferior to those against filovirus infections. Favipiravir should currently be considered as the most effective nonspecific medication against hemorrhagic fevers caused by arenaviruses.
About the Authors
Т. Е. Sizikova
48 Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
Tatiana E. Sizikova — Ph. D. in Biology
Sergiev Posad
V. N. Lebedev
48 Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
Vitaliy N. Lebedev — D. Sc. in Biology, Professor, Leading Researcher
Sergiev Posad
S. V. Borisevich
48 Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
Sergey V. Borisevich — D. Sc. in Biology, Professor, Academician of the Russian Academy of Sciences, Head of the Institute
Sergiev Posad
References
1. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T.Jr., Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol. 1987; 134: 5–68. doi: 10.1007/978-3-642-71726-0_2.
2. Radoshitzky S.R., Bao Y., Buchmeier M.J., Charrel R.N., Clawson A., Clegg C., DeRisi J.L., Gonzales J.P., Kuhn J.H., Lukashevich I.S., Peters C.J., Romanowski V., Salvato M.S., Stanglein M.D., de la Torre J.C. Past, present and future of arenavirus taxonomy. Arch Virol. 2015; 160 (7): 1851–1874. doi: 10.1007/s00705-015-2418-y.
3. Charrel R.N., de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res. 2003; 57 (1–2): 89100. doi: 10.1016/s0166-3542(02)00202-4.
4. Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., Khristova M.L., Weyer J., Swanepoel R., Egholm M., Nichol S.T., Lipkin W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009; 5 (5): 1–8. doi: 10.1371/journal.ppat.1000455.
5. Delgado S., Erickson B.R., Agudo R., Blair P.J., Vallejo E., Albariño C.G., Vargas J., Comer J.A., Rollin P.E., Ksiazek T.G., Olson J.G., Nichol S.T. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008; 4 (4): 1–6. doi: 10.1371/journal.ppat.1000047.
6. Emia D.A., Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994; 23(1): 23–31. doi: 10.1016/0166-3542(94)90030-2.
7. Gonsales J.P., Bowen M.D., Nichol S.T., Rico-Hesse R. Genetic characterization and phylogeny of Sabia virus, an emergent pathogen in Brazil. Virology. 1996; 221 (2): 318–324. doi: 10.1006/viro.1996.0381.
8. Kranzusch P.J., Schenk A.D., Rahmeh A.A., Radoshitzky S.R., Bavari S., Walz T., Whelan S.P. Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci USA. 2010; 107 (46): 20069–74. doi: 10.1073/ pnas.1007152107.
9. Salas R., de Manzione N., Tesh R. et al. Venezuelan hemorrhagic fever. Lancet. 1991; 338: (8774): 1033–1036. doi: 10.1016/0140-6736(91)91899-6.
10. McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr Top Microbiol Immunol. 2002; 262: 75–109. doi: 10.1007/978-3-642-56029-3_4.
11. Radoshitzky S.R., Kuhn J.H., de Kok-Mercado F., Jahrling P.B., Bavari S. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin Drug Discov. 2012; 7 (7): 613–32. doi: 10.1517/17460441.2012.687719.
12. Emia D.A., Barrera O.J.G. Junin virus vaccines /In: Oldstone M.B.A. Arenaviruses II The Molecular pathogenesis of arenavirus infections. Springer Verlag, Berlin, 2002.
13. Barry M., Russi M., Armstrong L., Geller D., Tesh R., Dembry L., Gonzalez J.P., Khan A.S., Peters C.J. Brief report: treatment of a laboratory-acquired Sabiá virus infection. N. Engl. J. Med. 1995; 333(5): 294–296. doi: 10.1056/NEJM199508033330505.
14. Emia D.A., Briggiler A.M., Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008; 78 (1): 132–9. doi: 10.1016/j.antiviral.2007.10.010.
15. Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., Fair J., Guttieri M.C., Ferro P., Imes T., Monagin C., Garry R.F., Bausch D.G. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 2008; 78 (1): 103–15. doi: 10.1016/j.antiviral.2007.11.003.
16. Cао W., Henry M.D., Borrow P., Yamada H., Elder J.H., Ravkov E.V., Nichol S.T., Compans R.W. Campbell K.P., Oldstone M.B. Identification of alphadystroglycan as a receptor for lymphocytes choriomeningitis virus and Lassa fever virus. Science. 1998: 282; 2079–2081.
17. Shao J., Liang Y., Ly H. Human hemorrhagic fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis. Pathogens. 2015; 4 (2): 283–306. doi: 10.3390/ pathogens4020283.
18. Helguera G., Jemielity S., Abraham J., Cordo S.M., Martinez M.G., Rodríguez J.A., Bregni C., Wang J.J., Farzan M., Penichet M.L., Candurra N.A., Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses. J Virol. 2012; 86 (7): 4024–4028. doi: 10.1128/JVI.06397-11.
19. Radoshitzky S.R.,Kuhn J.H., Spiropoulo C.F., Albarino G.G., Nguyen D.P., Salazar-Bravo J., Dortman T., Lee A.S., Wang E., Ross S.R. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. PNAS USA. 2008; 105: 2664–2669. doi: 10.1073/pnas. 0709254105.
20. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117 (3): 285–297. doi: 10.1016/s0092-8674(04)00343-5.
21. Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Günther S., Canard B. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog. 2010; 6 (9): 1–11. doi: 10.1371/journal.ppat.1001038.
22. Brunotte L., Kerber R., Shang W., Hauer F., Hass M., Gabriel M., Lelke M., Busch C., Stark H., Svergun D.I., Betzel C., Perbandt M., Günther S. Structure of the Lassa virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray scattering, and electron microscopy. J Biol Chem. 2011; 286 (44): 38748–56. doi: 10.1074/jbc.M111.278838.
23. Hastie K.M., Liu T., Li S., King L.B., Ngo N., Zandonatti M.A., Woods V.L.Jr., de la Torre J.C., Saphire E.O. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci USA. 2011; 108 (48): 19365–70. doi: 10.1073/pnas.1108515108.
24. Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Lund S.A., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006; 69 (2): 86–97. doi:10.1016/ j.antiviral. 2005.10.008.
25. Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008; 82 (21): 10768–75. doi: 10.1128/JVI.00941-08.
26. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem. 2008; 283 (27): 18734–42. doi: 10.1074/jbc.M802089200.
27. Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One. 2008; 3 (11): 1– 11. doi: 10.1371/journal.pone.0003725.
28. Sepúlveda C.S., García C.C., Fascio M.L., D'Accorso N.B., Docampo Palacios M.L., Pellón R.F., Damonte E.B. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res. 2012; 93 (1): 16–22. doi: 10.1016/j.antiviral.2011.10.007.
29. García C.C., Candurra N.A., Damonte E.B. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antivir Chem Chemother. 2000; 11 (3): 231–237. doi: 10.1177/095632020001100306.
30. García C.C., Candurra N.A., Damonte E.B. Mode of inactivation of arenaviruses by disulfide-based compounds. Antiviral Res. 2002; 55 (3): 437–446. doi: 10.1016/s0166-3542(02)00076-1.
31. García C.C., Ellenberg P.C., Artuso M.C., Scolaro L.A., Damonte E.B. Characterization of Junín virus particles inactivated by a zinc finger-reactive compound. Virus Res. 2009; 143 (1): 106–113. doi: 10.1016/j.virusres.2009.03.010.
32. García C.C., Topisirovic I., Djavani M., Borden K.L., Damonte E.B., Salvato M.S. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun. 2010; 393 (4): 625–630. doi: 10.1016/j.bbrc. 2010.02.040.
33. García C.C., Candurra N.A., Damonte E.B. Differential inhibitory action of two azoic compounds against arenaviruses. Int J Antimicrob Agents. 2003; 21 (4): 319–324. doi: 10.1016/s0924-8579(02)00390-4.
34. Albiol Matanic V.C., Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents. 2004; 23 (4): 382–389. doi: 10.1016/j.ijantimicag.2003.07.022.
35. Barradas J.S., Errea M.I., D'Accorso N.B., Sepúlveda C.S., Talarico L.B., Damonte E.B. Synthesis and antiviral activity of azoles obtained from carbohydrates. Carbohydr Res. 2008; 343 (14): 2468–2474. doi: 10.1016/j.carres.2008.06.028.
36. Dunning J., Sahr F., Rojek A., Gannon F., Carson G., Idriss B., Massaquoi T., Gandi R., Joseph S., Osman H.K., Brooks T.J., Simpson A.J., Goodfellow I., Thorne L., Arias A., Merson L., Castle L., Howell-Jones R., PardinazSolis R., Hope-Gill B., Ferri M., Grove J., Kowalski M., Stepniewska K., Lang T., Whitehead J., Olliaro P., Samai M., Horby P.W. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016; 13 (4): 1–19. doi: 10.1371/journal. pmed.1001997.
37. Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V., Johnson J.C., de Jong S., Tavakoli I., Judge A., Hensley L.E., Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375 (9729): 1896–905. doi: 10.1016/S0140-6736(10)60357-1.
38. Thi E.P., Mire C.E., Lee A.C.H., Geisbert J.B., Zhou J.Z., Agans K.N., Shead N.M., Deer D.J., Barbard T.R., Fenton K.A., MacLachlian I., Geisbert T.W. Lipid nanjparticle siRNA treatment of Ebola virus Makona infected primates. Nature. 2015; 521 (7552): 362–365. doi: 10.1038/nature14442.
Review
For citations:
Sizikova Т.Е., Lebedev V.N., Borisevich S.V. The Estimation of Efficacy of Nonspecific Medications Against Hemorrhagic Fevers Caused by Arenaviruses. Antibiot Khimioter = Antibiotics and Chemotherapy. 2023;68(7-8):70-77. (In Russ.) https://doi.org/10.37489/0235-2990-2023-68-7-8-70-77
Views:
203
Email this article 